Check Point Software Technologies Ltd vs Pfizer Inc — how do they compare? Check Point Software Technologies Ltd trades at $129.01 (market cap $13.39B), while Pfizer Inc trades at $26.54 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 11.5× Check Point Software Technologies Ltd's market cap, and Pfizer Inc pays a 6.36% dividend while Check Point Software Technologies Ltd pays none. Which is the better fit depends on your goals.
| CHKP | PFE | |
|---|---|---|
Market Cap | $13.39B | $154.18B |
Sector | Technology | Health |
52-Week High | $206.91 | $28.56 |
52-Week Low | $112.47 | $23.60 |
Enterprise Value | $13.09B | $205.67B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.36% |
Signals from Pluang's Aura AI — not financial advice
Check Point Software (CHKP) trades at $127.82, up 2.03% today, but remains in a bearish technical trend. The company maintains strong profitability with 37.93% net margins and has beaten earnings estimates for three consecutive quarters. Recent news includes insider selling by the CRO and recognition as a visionary leader in enterprise risk management platforms. Technical indicators show oversold conditions with RSI at 24.45, suggesting potential for near-term bounce.
CHKP presents a value opportunity with attractive P/E of 13.45, trading below analyst consensus target of $146.92. However, structural challenges in hardware demand and margin compression create headwinds. The stock's 36% decline year-to-date may have created a buying opportunity for patient investors, though near-term volatility is expected given bearish technical signals and mixed analyst sentiment.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Trailing returns across standard periods
Latest headlines on both assets
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →